Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Western Alliance Bancorporation — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Western Alliance Bancorporation trades at $72.03 (market cap $8.04B). The key difference: Spyre Therapeutics Inc. Common Stock and Western Alliance Bancorporation are close in size by market cap, and Western Alliance Bancorporation pays a 2.28% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Western Alliance Bancorporation for 3 Days on average.
| SYRE | WAL | |
|---|---|---|
Market Cap | $7.52B | $8.04B |
Volume | 1,441,031 | 1,433,355 |
Sector | Health | Financials |
52-Week High | $108.92 | $96.08 |
52-Week Low | $22.18 | $66.70 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $6.52B | $9.57B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Western Alliance Bancorporation (WAL) trades at $73.73, down 1.29% on the day, reflecting a bearish technical signal despite strong fundamentals. The stock shows solid profitability with a 25.43% net income margin and attractive valuation ratios, including a P/E of 8.32. Recent earnings have mostly beaten estimates, and the company launched WA VenueX, a new financial platform. Analyst consensus is strongly bullish with a $85.09 price target, though technical indicators point to near-term weakness.
The outlook for WAL is positive based on fundamentals and analyst support, but technical headwinds and interest rate sensitivity pose risks. Upside potential exists if the stock rebounds from support levels and executes on growth initiatives, while downside could stem from macroeconomic pressures or missed earnings. The high institutional ownership and recent dividend announcement signal confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
